SGRY Reiterated by TD Cowen -- Price Target Maintained at $19
TD Cowen reiterated a 'Buy' rating for Surgery Partners (SGRY) with a $19 price target. The stock is seen as 46.8% undervalued with a GF Value of $24.81. Insider buying totaled $143,500 over 3 months. The company operates surgical facilities, focusing on cost-effective outpatient care. Its GF Score is 59, indicating moderate performance.
How this was made
The 30-second read
Why it matters
Analyst reiteration provides limited new information; price target unchanged suggests no fresh catalyst.
Market read
A routine analyst rating reaffirmation with modest upside potential; unlikely to drive significant trading activity.
What to watch
Insider buying is modest and may not signal strong confidence; valuation still appears high relative to earnings.
Background
Surgery Partners operates ambulatory surgery centers and hospitals, trading at a discount to its internal valuation model.
Ticker impact
TD Cowen reiterated a Buy rating and kept the $19 price target for Surgery Partners.
Small upside potential if investors follow the target, but no catalyst for a sharp move.
The rating is a repeat, not a new upgrade or new data; market likely already priced the view.
Market effects
Reinforces a positive outlook for outpatient surgery services but limited sector-wide impact.
US healthcare sector sees modest sentiment boost.
Low; the story is company‑specific.
Counterpoint
The stock remains unprofitable with weak financial strength; investors may stay cautious despite the rating.
Key entities
- Analyst FirmTD Cowen
Issued the rating reaffirmation.
- CompanySurgery Partners Inc.
Subject of the rating update.
